drugset / Trial / NCT02705378

The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit

NCT02705378 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.

Timeline

Start
2017-05
Primary completion
2019-04
Completion
2019-12

Outcome

Outcome not reported

Stopped: “PI left institution. Protocol never submitted to the IRB, no contract executed only Confidentiality Agreement, and study not done.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxegol Unknown 25 mg Other
Comparator polyethylene glycol Other / unclassified 17 g Other

Indications